T he end point of ventricular tachycardia (VT) ablation studies should ideally predict the target outcome-freedom from VT recurrence. VT in patients with previous myocardial infarction is often due to scar-related re-entry. This is supported, although not proven, by the fact that VT can be initiated by programmed electric stimulation (PES). Entrainment and resetting with fusion are strong arguments for re-entry but can be only performed during hemodynamically tolerated VT.
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The substrate for re-entry is characterized by regions of slow conduction, unidirectional conduction block that allows initiation of re-entry, and areas of conduction block that can define parts of the re-entry circuit. Conduction block can be anatomically fixed but also functional and thus only present during VT or at rapid rates. Catheter ablation aims to transect the critical isthmus of the re-entry circuit.
The ideal ablation candidate is inducible for the clinically documented, hemodynamically tolerated VT. This allows for detailed analysis of the mechanism involved and accurate delineation of the underlying substrate. Unfortunately, this scenario applies only to a minority (albeit an important number) of patients.
This first patient category was accepted for ablation in the early 1990s. Only the clinical VT was targeted and of importance, was, without exception reproducibly inducible from the right ventricle. 1 Outcome was favorable if the clinical VT was abolished, a result achieved in 75% of the patients. Remarkably, 82% of them were noninducible for any VT after ablation. In 16% of these noninducible patients, ventricular arrhythmia (VA) recurred; in half of the patients early and often with the same VT morphology, perhaps due to lesion recovery. Patients presenting with a late recurrence either died suddenly, presumably (but not definitively) arrhythmic, or had a not previously documented VT. Patients with VA recurrence were more likely to be inducible for nonclinical VT.
The second patient category was patients presenting with stable VTs but had multiple inducible VTs, of which all tolerated VTs were targeted. 2 In 85%, the clinical VT could be abolished, but only 31% were rendered uninducible, despite a more extensive ablation approach. The difference in acute outcome may be partly explained by the more impaired ejection fraction (EF) in this second category. VT recurred in only 9% of noninducible patients but in 47% of patients with inducible nonclinical VTs after ablation. The latter had more inducible VTs, and the remaining VTs were faster than the ablated VTs.
With the widespread use of implantable cardioverter defibrillators (ICDs), a third patient category has entered the electrophysiology laboratory. The majority have advanced heart failure and not tolerated VTs. For unstable VTs and for VTs that are documented but not inducible, it is impossible to verify the mechanism and to prove a causal relationship between the arrhythmia and the targeted substrate. It is important to remember that much of our knowledge about mechanism and substrate of postinfarct VT is derived from mapping studies performed in patients without infarct reperfusion therapy, inducible for tolerated, often aneurysm-related VTs. Based on the assumption that the majority of postinfarct VTs have similar underlying substrates that can be identified by catheter mapping during sinus rhythm, substrate-guided approaches have increasingly been used. Ablation targets surrogates for VT isthmuses and exit sites based on pace-mapping and abnormal electrograms that are consistent with slow conduction or poor coupling. Despite these new techniques, short-term success rates are disappointing with high recurrence rates usually within the first 6 to 12 months after the procedure.
As any region of slow conduction may serve as substrate for later VTs, elimination of all abnormal electrograms has been suggested as a new ablation end point. 3 Patients in whom it was possible to eliminate all abnormal potentials had a better outcome than those with persistent abnormal electrograms. However, 6-month VT-free survival in the successful group was still suboptimal.
Before introducing new ablation end points that may require more invasive, extensive, and time-consuming procedures likely to be associated with more patient discomfort and procedural related complications, it is important to evaluate what has been applied in many laboratories for >2 decades.
In this issue of Circulation: Arrhythmia and Electrophysiology, Ghanbari et al 4 report the results of a meta-analysis to provide more precise estimates of the value of noninducibility of postinfarct VTs after ablation for prediction of VT/ventricular fibrillation (VF) recurrence and all-cause mortality. The authors should be congratulated for the effort put into the thorough analysis of publications on postinfarct VT ablation. It is remarkable that the extensive search revealed only 8 suitable studies, all observational cohort studies published between 1994 and 2013, enrolling 928 patients. Inclusion required implementation of postablation PES with an accepted stimulation protocol and the report of outcome data depending on inducibility after ablation. Pooling the results, the authors demonstrated that patients who remain inducible for a clinically documented VT, accounting for 12.5% of all patients, were more likely to experience VT/VF recurrence than noninducible patients (odds ratio, 0.1; 95% confidence interval, 0.06-0.18) or patients only inducible for previously undocumented VTs (odds ratio, 0.24; 95% confidence interval, 0.13-0.45). In 82.3% of these patients, VT/ VF recurred. These data nicely support the recent expert consensus that endorses noninducibility of the clinical VT as a minimum end point for ablation, provided that the VT has indeed been adequately documented previously and can be induced at the outset of the procedure. 5 The prognostic significance of VTs that have not occurred spontaneously is less clear. Distinguishing clinical from nonclinical VTs has many well-recognized limitations if only cycle length and intracardiac electrograms are analyzed. Even 12-lead ECGs may be misleading as the same substrate can be related to different VT morphologies. With this limitation that applies to all studies, it may be reasonable to aim for complete elimination of all induced VTs. This was the predefined ablation end point in 6 of the 8 studies included in the meta-analysis and achieved in ≈64% of patients. However, noninducibility varied between studies, ranging between 52% and 81% despite similar approaches, all performed in experienced centers, and may be mainly due to the heterogeneity of patients included. Patients noninducible for any VT after ablation had a 50% lower risk for recurrent VT/VF than patients who remain inducible for a nonclinical VT, keeping the above-mentioned limitation in mind.
Noninducible patients not only had a better outcome regarding arrhythmic events but also had a lower risk of allcause mortality compared with those who remained inducible for clinical or nonclinical VTs. It does, however, not follow logically that this is an effect of the ablation procedure, as it might well be that it reflects underlying clinical differences between patients.
Should we use elimination of induced VT as routine end point? Looking at the provided pooled data of 6 studies, it is important to recognize that despite noninducibility, VT/VF recurred in ≈31%. On the other hand, 54% of all patients who remained inducible for a previously undocumented VT had no VT/VF recurrence, suggesting that in these patients elimination of the clinically documented VT may be sufficient. Any additional intervention would lead to overtreatment and potential harm.
The result of one test, PES, performed immediately after ablation cannot predict freedom from VAs and all-cause mortality. Not all VTs are due to fixed re-entry and, in particular in patients with heart failure, there might be high competing risks of nonfixed re-entry mechanisms and of nonarrhythmic death.
Conduction slowing can be not only due to fibrosis and cellular uncoupling but also due to ischemia and electrolyte imbalance. With progressive heart failure, ionic and molecular remodeling can lead to conduction anisotropy and dispersion of refractory period. The latter may contribute to a VA substrate not restricted to the dense scar and its border zone, currently targeted by catheter ablation. 6 Furthermore, other reentry mechanisms may cause VTs. Spiral wave re-entry may appear as monomorphic VT if anchoring to a region of scar. Finally, focal nonre-entrant mechanisms like triggered activity, also inducible by PES, may play a role. 7 To date, there is insufficient data on the clinical relevance, (re)inducibility, and specific substrate requirements for these arrhythmia mechanisms. In this context, the results of a recently conducted ablation study, using the combined end point of noninducibility and late potential ablation, are noteworthy. 8 Patients who had late potential at the start of the procedure that could be abolished and who were noninducible after ablation had 16% VT recurrence. By contrast, patients who were rendered noninducible but in whom late potential could not be abolished had 47% VT recurrence shortly after ablation. Significantly, 70% of these noninducible patients had no late potential at the start of the procedure, suggesting a different substrate for VA not detectable by current mapping techniques.
From the Multicenter Un-Sustained Tachycardia Trial, we have learned that EF can influence the predictive value of inducibility for arrhythmic events. Among those with an EF≥30%, 61% of all deaths were arrhythmic in patients with inducible VT, but only 42% of the deaths were arrhythmic in noninducible patients. By contrast, in patients with EF<30%, no difference in arrhythmic deaths was observed between inducible and noninducible patients. Inducibility seemed to be a relatively specific predictor for arrhythmic events only in patients with an EF between 30% and 40%. Although arrhythmias accounted for a similar percentage of deaths in patients with an EF above and below 30%, the mechanisms underlying the events may be different and not all detected by current PES. 9 The Multicenter Automatic Defibrillator Implantation Trial II included patients after myocardial infarction with an EF <30%, and although not mandatory, the majority underwent PES before ICD implantation. Interestingly, 9% of noninducible patients had ≥1 episode of VF at 3 years. 10 Although not targeted, these episodes also count as VA recurrence in ablation studies.
The value of inducibility to predict arrhythmias may also be influenced by early reperfusion during the index infarction. Among patients who present with VA before ICD implantation, reperfused patients were less likely to be inducible for VT compared with nonperfused patients with a similar EF. Despite similar VT induction rates in reperfused and nonreperfused patients without previously documented VA, reperfused patients were at lower risk for spontaneous VT. 11 Is noninducibility a reasonable end point for VT ablation? Using current ablation approaches, the substrate for fixed reentry, proven by entrainment mapping or assumed based on electrogram characteristics, is targeted. Therefore, ablation can contribute to freedom from monomorphic VT recurrence because of this specific substrate. To expect any other outcome would perhaps be too ambitious. In patients with this substrate, PES is an appropriate test and noninducibility may be considered as the ideal end point.
Patients who remain inducible may have a different substrate and perhaps nonfixed re-entry mechanism not sufficiently targeted by current ablation approaches. These patients need a better ablation strategy, but perhaps the same end point. Noninducible patients in whom VA recur may not only have lesion recovery but may also have different VA mechanisms not reliably detectable by PES. For these patients, PES is not the correct test.
Unfortunately, none of the included studies controlled for patient characteristics known to influence VT inducibility and outcome when comparing patients with and without inducible VTs after ablation. A more powerful approach would be to obtain data on each individual patient, and the authors should be strongly encouraged to take this additional effort.
Although suggested, a randomized trial to predict outcome after ablation based on PES may not be feasible. Procedural outcomes like noninducibility are not interventions that can be randomized, and these outcomes are likely influenced by the underlying substrate. However, we can randomize well-defined cohorts to well-defined ablation strategies. We then hopefully will be able to identify patients who benefit from ablation with the end point noninducibility, patients who require more extensive substrate ablation and additional end points, as well as those who do not benefit from further ablation but require different treatment strategies for a substrate that is as yet poorly understood. Until these data become available, we should use noninducibility as the end point for VT ablation but not at any cost. We need to carefully consider patient characteristics and operator experience to make sure that the benefit for each individual patient outweighs procedural risks.
